Advertisement

Topics

High Affinity Cross Species Single Domain Antibodies Targeting Mesothelin

20:00 EDT 14 May 2019 | NIH

Mesothelin is a cell surface protein that is an excellent target for immunotherapy because of its limited expression on normal tissues and its high expression on many cancers, including mesothelioma, cholangiocarcinoma, pancreatic, ovarian, lung, stomach, bile duct, and triple-negative breast cancer.

Researchers at the National Cancer Institute’s (NCI) Laboratory of Molecular Biology have isolated two anti-mesothelin single domain antibodies (also known as nanobodies), A101 and G8. These antibodies have been isolated from newly developed camel single domain (VHH) libraries by phage display and have been used to shown to specifically target mesothelin-expressing cell lines with high affinity. Additionally, these mesothelin antibodies can be used as either independent agents or targeting domains in recombinant immunotoxins (RITs), antibody-drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptors (CARs). Significantly, CARs using these antibodies have shown specific killing activity against mesothelin positive tumors including mesothelioma cell and mouse models, strongly supporting that these candidates may be further developed as therapeutics.  

IC: 
NCI
NIH Ref. No.: 
E-040-2019
Advantages: 
  • New A101 and G8 antibodies with high mesothelin binding specificity should result in less non-specific cell killing and lower-grade potential side-effects
  • Similarity of camel and human VH sequences suggests humanization of these antibodies is not necessary, and that the product is ready for immediate clinical testing
  • CARs using the A101 and G8 antibodies are available for immediate testing
Applications: 
  • Therapeutic applications include the unconjugated antibodies and their use as a targeting moiety for CARs, RITs, ADCs, and bispecific antibodies
  • Diagnostic agent for detection and monitoring levels of mesothelin expressing cancers
Development Status: 

Pre-clinical (in vivo)

Updated On: 
May 15, 2019
Date Published: 
Wednesday, May 15, 2019
Provider Classifications: 
Publications: 
Patent Application: 
62/789,650
Licensing Contacts: 
Lead Inventor: 
Inventor IC: 
NCI
NCI
NCI
NCI
Inventor Lab URL: 
https://ccr.cancer.gov/Laboratory-of-Molecular-Biology/mitchell-ho
https://ccr.cancer.gov/Laboratory-of-Molecular-Biology/ira-pastan
LPM FIrst Name: 
John
LPM Last Name: 
Hewes
Inv Is lead: 
LPM Phone: 
240-276-5515
LPM Suffix: 
Ph.D.
LPM Organization: 
NCI - National Cancer Institute
DTDT Classification: 
Therapeutics
DTDT Description: 
Therapeutics
Pat Filing Date: 
2019-01-08
Collaboration Sought: 
Yes
Institute or Center: 
Collaboration Opportunity: 

Licensing and research collaboration

E Number Only: 
E-040-2019
Inventor First Name: 
Mitchell
Ira
Jessica
Nan
Inventor Last Name: 
Ho
Pastan
Hong
Li

Original Article: High Affinity Cross Species Single Domain Antibodies Targeting Mesothelin

NEXT ARTICLE

More From BioPortfolio on "High Affinity Cross Species Single Domain Antibodies Targeting Mesothelin"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...